痛风伴高尿酸血症采用非布司他治疗的效果观察  

Observation of the therapeutic effect of febuxostat on gout complicated with hyperuricemia

作　　者：严蕴霞 谢丹 邢媛 瞿怡倩 刘闻莺 YAN Yun-xia;XIE Dan;XING Yuan(Putuo District Zhenru Town Street Community Health Service Center,Shanghai 200333,China)

机构地区：[1]上海普陀区真如镇街道社区卫生服务中心,200333

出　　处：《中国实用医药》2025年第7期94-97,共4页China Practical Medicine

摘　　要：目的分析痛风伴高尿酸血症采用非布司他治疗的效果。方法200例痛风伴高尿酸血症患者,随机分为观察组与对照组,各100例。观察组患者接受非布司他治疗,对照组患者接受别嘌醇治疗。对比两组患者的临床疗效,尿酸水平,炎性因子[肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)、C反应蛋白(CRP)、降钙素原(PCT)]水平,不良反应发生情况。结果观察组总有效率99.00%高于对照组的92.00%(P<0.05)。治疗后,观察组尿酸(293.86±32.57)μmol/L低于对照组的(426.37±21.37)μmol/L(P<0.05)。治疗后,观察组TNF-α、IFN-γ、CRP、PCT分别为(8.45±1.57)pg/ml、(2.76±1.37)ng/ml、(8.96±3.52)mg/L、(2.18±0.74)ng/ml,低于对照组的(13.82±2.31)pg/ml、(4.16±1.24)ng/ml、(13.27±2.73)mg/L、(5.52±1.43)ng/ml(P<0.05)。观察组不良反应发生率1.00%低于对照组的8.00%(P<0.05)。结论非布司他在痛风伴高尿酸血症患者的临床治疗中具有较为显著的作用,可有效降低患者尿酸水平与炎性因子水平,并可降低患者不良反应发生风险,对改善患者预后具有较为显著的作用,值得广泛推广。Objective To analyze the therapeutic effect of febuxostat on gout complicated with hyperuricemia.Methods 200 patients with gout and hyperuricemia were randomly divided into an observation group and a control group,with 100 cases in each group.The observation group received treatment with febuxostat,while the control group received treatment with allopurinol.Comparison of the clinical efficacy,uric acid levels,levels of inflammatory factors[tumor necrosis factor-α(TNF-α),interferon-γ(IFN-γ),C-reactive protein(CRP),procalcitonin(PCT)],and incidence of adverse reactions between the two groups of patients.Results The total effective rate of 99.00%in the observation group was higher than 92.00%in the control group(P<0.05).After treatment,the the observation group had a lower uric acid of(293.86±32.57)μmol/L than(426.37±21.37)μmol/L in the control group(P<0.05).After treatment,TNF-α,IFN-γ,CRP and PCT in the observation group were(8.45±1.57)pg/ml,(2.76±1.37)ng/ml,(8.96±3.52)mg/L and(2.18±0.74)ng/ml,which were lower than(13.82±2.31)pg/ml,(4.16±1.24)ng/ml,(13.27±2.73)mg/L and(5.52±1.43)ng/ml in the control group(P<0.05).The incidence of adverse reactions of 1.00%in the observation group was lower than 8.00%in the control group(P<0.05).Conclusion Febuxostat plays a significant role in the clinical treatment of patients with gout and hyperuricemia.It can effectively reduce the levels of uric acid and inflammatory factors in patients,reduce the risk of adverse reactions in patients,and has a significant effect on improving the prognosis of patients,which is worthy of widespread promotion.

关 键 词：痛风 高尿酸血症 非布司他 

分 类 号：R589.7[医药卫生—内分泌]